Performance and Clinical Utility of Models Predicting Eradication of Nodal Disease in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy by Tumor Biology
| Autor: | Mara A. Piltin, Mark Wickre, Tanya L. Hoskin, John M. Davis, Judy C. Boughey, Courtney N. Day, Abigail S. Caudle |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Biology Neoadjuvant therapy Chemotherapy business.industry Area under the curve Cancer Nomogram medicine.disease Neoadjuvant Therapy Axilla medicine.anatomical_structure 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Surgery business |
| Zdroj: | Annals of Surgical Oncology. 27:4678-4686 |
| ISSN: | 1534-4681 1068-9265 |
| Popis: | Prediction models are useful to guide decision making. Our goal was to compare three published nomograms predicting axillary response to neoadjuvant chemotherapy (NAC), clinically node-positive breast cancer. Patients with cT1–T4, cN1–N3 breast cancer treated with NAC and surgery from 2008 to 2019 were reviewed. The predicted probability of pathologic node-negative (ypN0) status was estimated for each nomogram. Area under the curve (AUC) was compared across models, overall and by biologic subtype. Of 581 patients, 253 (43.5%) were ypN0. ypN0 status varied by subtype: 23.9% for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−), 68.9% for HER2-positive (HER2+), and 47.2% for ER-negative (ER−)/HER2−. The three nomograms had similar AUC values (0.761–0.769; p = 0.80). The Mayo model-predicted probability was significantly lower (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink